183 related articles for article (PubMed ID: 32544354)
1. FDA approved vs. Pharmacy compounded 17-OHPC-current issues for obstetricians to consider in reducing recurrent preterm birth.
Gandell DL; Randell MD; Gudeman JL
Curr Med Res Opin; 2020 Aug; 36(8):1393-1401. PubMed ID: 32544354
[TBL] [Abstract][Full Text] [Related]
2. Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale.
Godlewski BJ; Sobolik LI; King VJ; Harrod CS
Obstet Gynecol; 2020 May; 135(5):1207-1213. PubMed ID: 32282587
[TBL] [Abstract][Full Text] [Related]
3. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Nelson DB; McIntire DD; Leveno KJ
Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
[TBL] [Abstract][Full Text] [Related]
4. Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate).
Cohen AW; Copel JA; Macones GA; Menard MK; Riley L; Saade GR
Obstet Gynecol; 2011 Jun; 117(6):1408-1412. PubMed ID: 21471853
[TBL] [Abstract][Full Text] [Related]
5. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
[TBL] [Abstract][Full Text] [Related]
6. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
Hines M; Lyseng-Williamson KA; Deeks ED
Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
[TBL] [Abstract][Full Text] [Related]
7. Utilization of hydroxyprogesterone caproate among pregnancies with live birth deliveries in the sentinel distributed database.
Shinde M; Cosgrove A; Woods CM; Chang C; Nguyen CP; Moeny D; Ajao A; Kolonoski J; Tsai HT
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6291-6296. PubMed ID: 33926341
[TBL] [Abstract][Full Text] [Related]
8. Qualitative and quantitative measures of various compounded formulations of 17-alpha hydroxyprogesterone caproate.
Caritis SN; Zhao Y; Bettinger J; Venkataramanan R
Am J Obstet Gynecol; 2013 Jun; 208(6):470.e1-5. PubMed ID: 23453884
[TBL] [Abstract][Full Text] [Related]
9. Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate.
;
Am J Obstet Gynecol; 2023 Jul; 229(1):B2-B6. PubMed ID: 37061078
[TBL] [Abstract][Full Text] [Related]
10. Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection.
Chollet JL; Jozwiakowski MJ
Drug Dev Ind Pharm; 2012 May; 38(5):540-9. PubMed ID: 22329865
[TBL] [Abstract][Full Text] [Related]
11. SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth.
Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: pubs@smfm.org
Am J Obstet Gynecol; 2020 Jul; 223(1):B16-B18. PubMed ID: 32277894
[TBL] [Abstract][Full Text] [Related]
12. A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production.
Megli CJ; Hauspurg A; Venkataramanan R; Caritis SN
Am J Perinatol; 2023 Oct; 40(14):1585-1589. PubMed ID: 34784615
[TBL] [Abstract][Full Text] [Related]
13. FDA Revokes Approval for Preterm Birth Drug Makena.
Harris E
JAMA; 2023 May; 329(17):1444. PubMed ID: 37043247
[No Abstract] [Full Text] [Related]
14. Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention.
Zhang S; Rascati KL
Curr Med Res Opin; 2021 Sep; 37(9):1667-1675. PubMed ID: 34030550
[TBL] [Abstract][Full Text] [Related]
15. Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
Fukuda T; Kyozuka H; Murata T; Yasuda S; Yamaguchi A; Fujimori K
J Obstet Gynaecol Res; 2021 Sep; 47(9):3119-3126. PubMed ID: 34219326
[TBL] [Abstract][Full Text] [Related]
16. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
[TBL] [Abstract][Full Text] [Related]
17. Withdrawing Approval of Makena - A Proposal from the FDA Center for Drug Evaluation and Research.
Chang CY; Nguyen CP; Wesley B; Guo J; Johnson LL; Joffe HV
N Engl J Med; 2020 Dec; 383(24):e131. PubMed ID: 33140923
[No Abstract] [Full Text] [Related]
18. Potential risks of pharmacy compounding.
Gudeman J; Jozwiakowski M; Chollet J; Randell M
Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
[TBL] [Abstract][Full Text] [Related]
19. Next generation strategies for preventing preterm birth.
Zierden HC; Shapiro RL; DeLong K; Carter DM; Ensign LM
Adv Drug Deliv Rev; 2021 Jul; 174():190-209. PubMed ID: 33895215
[TBL] [Abstract][Full Text] [Related]
20. Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate.
Hauspurg A; Lemon LS; Serra AE; Sharma S; Venkataramanan R; Caritis SN
Am J Perinatol; 2018 Jul; 35(9):809-814. PubMed ID: 29294501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
